The original patent for Humulin expired in 1994 [1]. However, subsequent patents related to its formulation and manufacturing processes have been filed and some may still be in effect [2].
When did the main Humulin patent expire?
The foundational patent for Humulin, a synthetic human insulin, expired in 1994 [1]. This marked the initial point at which generic versions could theoretically enter the market, though manufacturing complexities and additional patents influenced market dynamics [2].
Are there still patents protecting Humulin?
While the primary patent expired, DrugPatentWatch.com indicates that patents relating to Humulin's specific formulations, manufacturing methods, or delivery systems may have been filed and could still be active [2]. These secondary patents can extend market exclusivity for certain aspects of the drug even after the main patent has lapsed.
What does patent expiry mean for Humulin?
Patent expiry generally allows for the introduction of generic competitors. However, the development and approval of generic insulin products, including biosimilars, can be a complex and lengthy process. The presence of subsequent patents on specific manufacturing techniques or formulations can also affect the timeline and feasibility of generic entry [2].
Who makes Humulin and its competitors?
Humulin is manufactured by Eli Lilly and Company [3]. Competitors in the insulin market include companies producing other human insulins, as well as insulin analogs and biosimilars. Major insulin manufacturers include Novo Nordisk and Sanofi, among others [4]. The landscape for insulin products is evolving with the introduction of newer, longer-acting insulins and biosimilar versions of existing insulins.